The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical
landscape of prostate cancer treatment. Both drugs were designed to further suppress …

In the last few years, the survival of patients with castration-resistant prostate cancer (CRPC)
has significantly improved as a result of the development of second-generation androgen …

Reactivated androgen receptor (AR) signaling drives castration‐resistant prostate cancer
(CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved …

Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling
continues to be the mainstay treatment of advanced-stage prostate cancer. The use of …

After initial response to androgen receptor (AR) targeting drugs abiraterone or
enzalutamide, most patients develop progressive disease and therefore, castration resistant …

The metabolic functions of androgen receptor (AR) in normal prostate are circumvented in
prostate cancer (PCa) to drive tumor growth, and the AR also can acquire new growth …

Simple Summary Prostate cancer is the second most common cancer in males. In prostate
cancer cells, androgens bind and activate the intracellular mediator called Androgen …

In recent years, in castration resistant prostate cancer (CRPC), several new drugs have
been approved that prolong overall survival, including enzalutamide and abiraterone, two …

The androgen signaling axis has been the main therapeutic target in the management of
advanced prostate cancer for several decades. Over the past years, significant advances …

The androgen receptor (AR) signaling axis drives all stages of prostate cancer, including the
lethal, drug-resistant form of the disease termed castration-resistant prostate cancer (CRPC) …